Vascular and mixed dementias

Similar documents
MCDB 4777/5777 Molecular Neurobiology Lecture 38 Alzheimer s Disease

Objectives. Aging and Forgetfulness Define Dementia Types of Dementia Treatment

Primary Care Update January 28 & 29, 2016 Alzheimer s Disease and Mild Cognitive Impairment

Cholinesterase inhibitors and memantine use for Alzheimer s disease TOPIC REVIEW

UPDATES TO NEUROCOGNITIVE DISORDERS IN DSM-5 and DSM-5 DESK REFERENCE UPDATED

Primary Endpoints in Alzheimer s Dementia

Normal and Abnormal Aging and the Brain. Joel Kramer, PsyD Saul Villeda, PhD Kristine Yaffe, MD

Emergency Room Treatment of Psychosis

Conjoint Professor Brian Draper

Dementa Formulary Guidance [v1.0]

Prescribing Framework for Donepezil in the Treatment and Management of Dementia

2012 Medical School for Actuaries Nov. 6-7, 2012 Session #1: Alzheimer s Disease

The Genetic Basis of Neurological Disorders

Alzheimer s disease. What is Alzheimer s disease?

Social Security Disability Insurance and young onset dementia: A guide for employers and employees

J/601/2874. This unit must be assessed in accordance with Skills for Care and Development s QCF Assessment Principles.

These guidelines are intended to support General Practitioners in the care of their patients with dementia both in the community and in care homes.

Mental health issues in the elderly. January 28th 2008 Presented by Éric R. Thériault

2014 Alzheimer s Disease Facts and Figures

How To Treat An Elderly Patient

Depression in Older Persons

Mr James Garrard University of Leicester May 2014

1 in 3 seniors dies with Alzheimer s or another dementia.

CRITERIA FOR AD DEMENTIA June 11, 2010

The diagnosis of dementia for people living in care homes. Frequently Asked Questions by GPs

Clinical Audit: Prescribing antipsychotic medication for people with dementia

Objectives. Evaluation of Memory Loss. Cognitive Impairment. Clinical Questions. Medicare Wellness Visit

2016 Programs & Information

2015 Alzheimer s Disease Facts and Figures

Donepezil, galantamine, rivastigmine and memantine for Alzheimer s disease

Dementia & Movement Disorders

Clinical guideline Published: 22 November 2006 nice.org.uk/guidance/cg42

THEORIES OF NEUROLOGICAL AGING AND DEMENTIA

Dementia with Lewy bodies

Update on Treatment of the Dementias

How To Write Long Term Care Insurance

Support Program for Improving Graduate School Education Advanced Education Program for Integrated Clinical, Basic and Social Medicine

Delivering Integrated Dementia Care: The 8 Pillars Model of Community Support

What is PD? Dr Catherine Dotchin MD MRCP Consultant Geriatrician

What is vascular dementia?

Dementia: Delivering the Diagnosis

Depression is a common biological brain disorder and occurs in 7-12% of all individuals over

2016 ALZHEIMER S DISEASE FACTS AND FIGURES

Geriatric Psychiatrists

Copywrite - Eric Freitag, Psy.D., 2012

Diagnosis and Initial Management of Cognitive Disorders

Assisted Living Nurse Competencies

Long Term Care Formulary HCD Anti-Dementia Drugs (e.g. donepezil, galantamine, rivastigmine, memantine)

Sandro Sorbi DIPARTIMENTO DI SCIENZE NEUROLOGICHE E PSICHIATRICHE

Teaching method: Lectures, and discussion.

Biomarkers for Alzheimer's Disease in Down Syndrome

How To Find Out If The Gulf War And Health Effects Of Serving In The Gulf Wars Are Linked To Health Outcomes

Alzheimer Disease (AD)

Johns Hopkins Memory & Alzheimer s Treatment Center

Why study clinical neuropsychology?

Alzheimer s and Depression: What is the Connection?

ITT Advanced Medical Technologies - A Programmer's Overview

Steps to getting a diagnosis: Finding out if it s Alzheimer s Disease.

Dr Ameenah Sorefan President ASSOCIATION ALZHEIMER 12 th GLOBAL CONFERENCE ON AGEING JUNE 2014

2013 Report. New York State Coordinating Council. For Services Related to Alzheimers Disease and. Other Dementias. Governor Andrew M.

THE DEPRESSION RESEARCH CLINIC Department of Psychiatry and Behavioral Sciences Stanford University, School of Medicine

DEPRESSION CARE PROCESS STEP EXPECTATIONS RATIONALE

Local Clinical Trials

Everyone has mild memory lapses from time to time. You go

Common causes of dementia

Strengthening of palliative care as a component of integrated treatment throughout the life course

Shared Care Guideline-Use of Donepezil, Galantamine, Rivastigmine and Memantine in Dementia

basics of alzheimer s disease What it is and what you can do

Version Module guide. Preliminary document. International Master Program Cardiovascular Science University of Göttingen

If you were diagnosed with cancer today, what would your chances of survival be?

p. 185 The director of the Nuclear Medicine Technology program is Cindy Turchin, MBA, RT(R)(N), CNMT

FUNCTIONAL EEG ANALYZE IN AUTISM. Dr. Plamen Dimitrov

Sinemet (Parkinson's Disease) - Forecast and Market Analysis to 2022

Epilepsy 101: Getting Started

Parkinson s Disease: Factsheet

Assessment Blueprint for Stroke Medicine. Mini- DOPS MSF SESR CBD TP A R area

Diagnostic and Statistical Manual of Mental Disorders (DSM-IV-TR) (APA, 2001) 10

Parkinson s Disease - A Junior Doctor s Survival Guide

Not All Clinical Trials Are Created Equal Understanding the Different Phases

January. Report of a Working Group for the Faculty of Old Age Psychiatry, Royal College of Psychiatrists.

Master of Physician Assistant Studies Course Descriptions for Year I

PSYC PSYCHOLOGY Calendar Proof

Course outline. Code: PSY754 Title: Clinical Health Psychology and Psychopharmacology

Technology appraisal guidance Published: 23 March 2011 nice.org.uk/guidance/ta217

KIH Cardiac Rehabilitation Program

Traumatic brain injury (TBI)

Pharmacology skills for drug discovery. Why is pharmacology important?

Diseases of the Nervous System. Neal G. Simon, Ph.D. Professor, Dept of Biological Sciences Lehigh University

Dementia: supporting people with dementia and their carers

Cognitive impairment (CI) in Multiple Sclerosis

The National Institute of Genomic Medicine (INMEGEN) was

Antipsychotic drug prescription for patients with dementia in long-term care. A practice guideline for physicians and caregivers

Clinical Features of Mild Cognitive Impairment and Dementia in a Community: An update of the Osaki-Tajiri Project

Dementia and cognitive decline

Graduate and Postdoctoral Affairs School of Biomedical Sciences College of Medicine. Graduate Certificate. Metabolic & Nutritional Medicine

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE SCOPE

Essential Shared Care Agreement Drugs for Dementia

Update of Pharmacological Intervention Recommendations for the Canadian Consensus Conference on the Diagnosis and Treatment of Dementia 2012

GUIDANCE AND COMPETENCES FOR THE PROVISION OF SERVICES USING GENERAL PRACTITIONERS WITH SPECIAL INTERESTS (GPwSI) IN DEMENTIA

Alzheimer's: The Latest Assessment and Treatment Strategies

Transcription:

Oxford Medicine Online You are looking at 1-10 of 35 items for: heart disease MED00840 oxford_textbooks_in_psychiatry Vascular and mixed dementias Robert Stewart DOI: 10.1093/med/9780199644957.003.0034 Vascular disease is the most important environmental risk factor for dementia but this research area has been hampered by inadequate outcome definitions in particular, a diagnostic system that attempts to separate overlapping and probably interacting pathologies. There is now substantial evidence that the well-recognised risk factors for cardiovascular disease and stroke are also risk factors for dementia, including Alzheimer s disease. However, these risk factors frequently act over several decades, meaning that the chances of definitive randomised controlled trial evidence for risk-modifying interventions are slim. This should not obscure the wide opportunity for delaying or preventing dementia through risk factor control and uncontroversial healthy lifestyles. Care should also be taken that comorbid cerebrovascular disease is not considered as excluding a diagnosis of Alzheimer s disease, particularly now that this determines treatment eligibility. Epidemiology of dementia Laura Fratiglioni and Chengxuan Qiu DOI: 10.1093/med/9780199644957.003.0031 This chapter deals with the occurrence, determinants and primary prevention of dementia. Dementia is one of the major causes of functional dependence, poor quality of life, institutionalisation and mortality among elderly people. The risk of dementia increases almost exponentially with advancing age. As the population ages, dementia poses a serious threat to public health and social welfare system of our society. Accumulating evidence suggests that cardiovascular risk factors significantly contribute to the development and expression of dementia. Thus, adequate management of vascular risk factors and related disorders can be one of the preventative strategies against cognitive ageing and dementia. In addition, psychosocial factors such as educational achievement, socially-integrated and mentally-stimulating lifestyles are critical for delaying the onset of dementia by increasing cognitive reserve. Taken together, maintaining vascular health and adopting a healthy cognitive lifestyle from a life-course perspective may be the most promising strategy to achieve late-life cognitive health. Page 1 of 5

Alzheimer s disease John-Paul Taylor and Alan Thomas DOI: 10.1093/med/9780199644957.003.0033 Alzheimer s disease (AD) is a well recognised clinicopathological entity and the most common cause of dementia. This chapter critiques the several sets of newly proposed criteria for making the diagnosis of (AD) at different stages in the disease process, in the context of demand for earlier diagnosis and emerging biomarkers. The differential diagnosis and types of different cognitive symptoms are reviewed and the prevalence and pattern of the many non-cognitive symptoms associated with AD are considered. The management of non-cognitive symptoms is also updated, especially the circumstances in which antipsychotic drugs might be prescribed. And finally a summary of our current understanding of the aetiology (evidence for risk and protective factors for AD ) and the prognosis for AD is provided. Neuropathology Johannes Attems and Kurt A. Jellinger DOI: 10.1093/med/9780199644957.003.0006 This chapter describes the main neuropathological features of the most common age associated neurodegenerative diseases including Alzheimer's disease, Parkinson's disease and dementia with Lewy bodies as well as other less frequent ones such as multiple system atrophy, Pick's disease, corticobasal degeneration, progressive supranuclear palsy, argyrophilic grain disease, neurofibrillary tangle dominant dementia, frontotemporal lobar degeneration with TDP-43 pathology and Huntington's disease. Likewise cerebral amyloid angiopathy, hippocampal sclerosis, vascular dementia and prion diseases are described. A main aim of this chapter is to assist the reader in interpreting neuropathological reports, hence criteria for the neuropathological classifications of the major diseases are provided. One section covers general considerations on neurodegeneration and basic pathophysiological mechanisms of tau, amyloid-#, #-synuclein, TDP-43 and prions are briefly described in the sections on the respective diseases. Finally, one section is dedicated to cerebral multimorbidity and we give a view on currently emerging neuropathological methods. Pharmacological treatment of dementia Roy W. Jones DOI: 10.1093/med/9780199644957.003.0038 Page 2 of 5

This chapter summarises the available clinical evidence for specific pharmacological treatments for dementia with a particular emphasis on practical considerations and realistic expectations of currently available anti-dementia drugs. It covers the treatment of both cognitive and non-cognitive symptoms. The search for specific treatments for dementia has inevitably concentrated on Alzheimer s disease (AD), partly because it is the commonest cause of dementia and partly because scientific progress has provided more potential therapeutic targets for AD than other dementias. AD is treated with AChEIs (donepezil, galantamine or rivastigmine) and the goals of treatment should be explained at the commencement of treatment. For DLB use AChEI, especially for hallucinations and other behavioural disturbance and consider memantine or increasing dose if BPSD symptoms persist. For VaD look for sources of emboli (e.g. carotid disease) and consider anticoagulation for atrial fibrillation and low dose aspirin. Ensure other relevant conditions (e.g. hypertension and diabetes) are being managed appropriately. Molecular genetics and biology of dementia Denise Harold and Julie Williams DOI: 10.1093/med/9780199644957.003.0008 Considerable progress has been made in our understanding of the genetics and molecular biology of dementia. In this chapter we focus predominantly on the most common form of dementia, Alzheimer s disease (AD), but also discuss vascular dementia and frontotemporal dementia. Genetic mutations have been identified that cause Mendelian subtypes of each disorder, and in recent years genome-wide association studies have greatly aided the identification of risk genes for more common forms of disease. For example, 9 susceptibility genes have been identified in AD in the past 3 years as a result of genomewide association studies, the first robust risk loci to be identified since APOE in 1993. This progress in genetic research is having a dramatic effect on our understanding of disease pathogenesis, by refining previous ideas and defining new primary disease mechanisms. Dementia with Lewy bodies and Parkinson s disease dementia Arvid Rongve and Dag Aarsland DOI: 10.1093/med/9780199644957.003.0035 Dementia with Lewy bodies and Parkinson s disease dementia belong to the #- synucleinopathies, a family of diseases pathologically characterized by aggregation of #- synuclein in Lewy bodies in the brain. In this chapter we present the epidemiological data for both conditions including new data on MCI. Clinical diagnostic criteria are reviewed and the different neuropathology staging systems for DLB and PDD and the most important genetic findings are considered. Biomarkers in DLB and PDD with particular focus on imaging techniques like CIT-SPECT and MRI are described. Important clinical symptoms Page 3 of 5

in both conditions are presented in detail and the most important clinical differential diagnoses are discussed. Pharmacological and non- pharmacological treatment of different symptoms in both conditions are discussed with particular emphasis on the choline esterase inhibitors and antipsychotic medications.new data on memantine are presented. Physical assessment of older patients Duncan Forsyth DOI: 10.1093/med/9780199644957.003.0011 Mental health problems may co-exist with or be the presenting feature of other medical illness in older age. All clinicians also need to consider the potential psychological impact of ill-health and its treatments on patients and their carers. This chapter gives a geriatrician s guide to comprehensive geriatric assessment, identifying physiological changes that occur with ageing and the potential mental health presentations of common medical conditions. The geriatric giants of falls, immobility, incontinence, delirium and drug toxicity are put in the context of maintaining higher-order cortical functioning to enable the individual to remain upright, mobile, continent and clear in their thinking. These are considered with admissions avoidance or safe discharge planning in mind. Biological aspects of human ageing Doug Gray, Carole Proctor, and Tom Kirkwood DOI: 10.1093/med/9780199644957.003.0001 At the molecular and cellular levels human ageing is characterized by the accumulation of unrepaired random damage, and an accompanying loss of function. A major source of damage is oxidative stress caused by the generation of reactive oxygen species as a byproduct of respiration. DNA and proteins are both susceptible to damage but whereas DNA damage repair systems exist, faulty proteins are generally removed by protein degradation systems. During ageing these systems become less efficient and the subsequent accumulation of damaged protein promotes protein aggregation, a process which is especially problematic in the ageing brain. Other aspects of ageing include genetic and epigenetic changes, mitochondrial dysfunction, telomere shortening, and cellular senescence, all subject to stochasticity. The complexity of the biology of ageing has led to an increase in the use of systems biology approaches whereby the use of mathematical modelling and bioinformatic tools complement the more traditional experimental approaches. Page 4 of 5

Epidemiology of old age psychiatry: an overview of concepts and main studies Thais Minett, Blossom Stephan, and Carol Brayne DOI: 10.1093/med/9780199644957.003.0005 Epidemiology is the foundation of public health and rational planning of services. In the field of old age psychiatry, the information provided by epidemiological research has been highly influential. As the world older population is growing proportionally faster than the other age segments, there is a continuous need for further epidemiological research in old age psychiatry. Neuropsychiatric conditions, such as depression and dementia, cognitive impairment, behavioural and functional decline, place a considerable onus on the health, social and economic systems. This chapter presents some of the world demographic data and basic epidemiological concepts, discusses some methodological issues in the epidemiology of mental disorders in old age, and presents a summary of many of the most important studies in this field. Page 5 of 5